Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

June 21, 2018

Study Completion Date

June 21, 2018

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

bimatoprost 0.03% plus timolol 0.5%

1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.

Trial Locations (15)

100005

Beijing Hospital, Beijing

100053

Xuanwu Hospital Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

100730

Beijing Tongren hospital Capital Medical University, Beijing

200031

Eye & ENT Hospital of Fudan University, Shanghai

210029

Jiangsu Province Hospital, Nanjing

300020

Tianjin Eye Hospital, Tianjin

300384

Tianjin Medical University Eye Hospital, Tianjin

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

325027

Eye Hospital of Wenzhou Medical University, Wenzhou

410011

Second Xiangya Hospital of Central South University, Changsha

430030

Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan

450003

Henan Provincial Eye Hospital, Henan

510060

Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou

610041

West China Hospital, Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02571712 - Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter